Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

Raymond James: Lannett Emerges From Levothyroxine Woes

Share:
Raymond James: Lannett Emerges From Levothyroxine Woes

Lannett Company, Inc. (NYSE: LCI) announced the amendment of its Senior Secured Credit Facility Term A loan of $275 million, which takes the company a step closer to emerging from debt following the loss of generic levothyroxine, according to Raymond James.

The Analyst

Analyst Elliot Wilbur maintains a Market Perform rating on Lannett.

The Thesis

Although the modification of the original Term A loan doesn’t change the cash outflow profile of principal obligations related to the loan, it “slightly loosen the shackles on the company” and “should afford ample ceiling well through loan maturity in 2020,” Wilbur said in a note. (See his track record here.) 

Lannett’s management projects the company’s adjusted EBITDA for fiscal 2020, or the 12 months ending September 2020, significantly ahead of Street estimates.

The company expects the 16 products that it has launched so far in 2018 to generate $75 million in revenue with margins of 35-40 percent through June 2019. the analyst said.

Further, the company plans to launch another 15-17 products by the end of fiscal 2019. These would mostly be internally developed products with equally high margins and a market value exceeding $5 billion, according to Raymond James. 

The drug gConcerta is likely to be a near-term catalyst, with a GDUFA date of Feb. 1, 2019, Wilbur said.

Sometime next year, more news should arrive from the FDA and the management on Numbrino — topical cocaine — which received a CRL in July, the analyst said. 

Price Action

Lannett shares were down 2.85 percent at $5.11 at the time of publication Thursday. 

Related Links:

Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

Latest Ratings for LCI

DateFirmActionFromTo
Mar 2019Initiates Coverage OnHold
Aug 2018MaintainsMarket PerformMarket Perform
Aug 2018DowngradesOutperformMarket Perform

View More Analyst Ratings for LCI
View the Latest Analyst Ratings

Posted-In: Elliot Wilbur Raymond JamesAnalyst Color Health Care Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (LCI)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BSXMaintains45.0
CLMaintains68.0
HPMaintains75.0
KMBMaintains145.0
AMNMaintains60.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Cresco Labs Approved For Ohio's First Medical Marijuana Dispensary

Mid-Afternoon Market Update: Crude Oil Up 2.8%; Tailored Brands Shares Plummet